Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang East-Asia Pharmaceutical Co's quarterly market cap
declined
from Sep. 2025 (¥2,227 Mil) to Dec. 2025 (¥2,042 Mil) but then
increased
from Dec. 2025 (¥2,042 Mil) to Mar. 2026 (¥2,392 Mil).
Zhejiang East-Asia Pharmaceutical Co's annual market cap
declined
from Dec. 2023 (¥3,008 Mil) to Dec. 2024 (¥2,261 Mil) and
declined
from Dec. 2024 (¥2,261 Mil) to Dec. 2025 (¥2,042 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zhejiang East-Asia Pharmaceutical Co's Enterprise Value for Today is ¥2,370 Mil.
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zhejiang East-Asia Pharmaceutical Co Market Cap Related Terms
Zhejiang East-Asia Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co Market Cap Chart
SHSE:605177 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang East-Asia Pharmaceutical Co Market Cap vs Biotechnology Industry
Zhejiang East-Asia Pharmaceutical Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a Market Cap of ¥1,732 Mil as of Jul. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #538 out of 1422 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Zhejiang East-Asia Pharmaceutical Co's Market Cap too high?
Zhejiang East-Asia Pharmaceutical Co's current Market Cap is ¥1,732 Mil. Based on the distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #538 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #538 out of 1422 companies for Market Cap. This puts Zhejiang East-Asia Pharmaceutical Co in the upper half of its industry. The industry median Market Cap is 110.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 110.32, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Market Cap is 110.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang East-Asia Pharmaceutical Co's current Market Cap is ¥1,732 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥12.42, compared to a current price of ¥15.10 — trading 21.6% above its estimated fair value. The current Market Cap is ¥1,732 Mil. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current Market Cap is ¥1,732 Mil as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.10 is trading 21.6% above its estimated GF Value™ of ¥12.42.
GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:605177:
Market Cap: ¥1,732 Mil
GF Value™: ¥12.42 vs. price of ¥15.10 (21.6% above fair value)
No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang East-Asia Pharmaceutical Co Business Description
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
57GF Score
Get the complete analysis for SHSE:605177
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605177 has been successfully added to your 
